@article{MTMT:3217843,
	title = {Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.},
	url = {https://m2.mtmt.hu/api/publication/3217843},
	author = {Yusuf, S and Bosch, J and Dagenais, G and Zhu, J and Xavier, D and Liu, L and Pais, P and Lopez-Jaramillo, P and Leiter, LA and Dans, A and Avezum, A and Piegas, LS and Parkhomenko, A and Keltai, Katalin and Keltai, Mátyás and Sliwa, K and Peters, RJ and Held, C and Chazova, I and Yusoff, K and Lewis, BS and Jansky, P and Khunti, K and Toff, WD and Reid, CM and Varigos, J and Sanchez-Vallejo, G and McKelvie, R and Pogue, J and Jung, H and Gao, P and Diaz, R and Lonn, E},
	doi = {10.1056/NEJMoa1600176},
	journal-iso = {NEW ENGL J MED},
	journal = {NEW ENGLAND JOURNAL OF MEDICINE},
	volume = {374},
	unique-id = {3217843},
	issn = {0028-4793},
	abstract = {BACKGROUND: Previous trials have shown that the use of statins to lower cholesterol reduces the risk of cardiovascular events among persons without cardiovascular disease. Those trials have involved persons with elevated lipid levels or inflammatory markers and involved mainly white persons. It is unclear whether the benefits of statins can be extended to an intermediate-risk, ethnically diverse population without cardiovascular disease. METHODS: In one comparison from a 2-by-2 factorial trial, we randomly assigned 12,705 participants in 21 countries who did not have cardiovascular disease and were at intermediate risk to receive rosuvastatin at a dose of 10 mg per day or placebo. The first coprimary outcome was the composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, and the second coprimary outcome additionally included revascularization, heart failure, and resuscitated cardiac arrest. The median follow-up was 5.6 years. RESULTS: The overall mean low-density lipoprotein cholesterol level was 26.5% lower in the rosuvastatin group than in the placebo group. The first coprimary outcome occurred in 235 participants (3.7%) in the rosuvastatin group and in 304 participants (4.8%) in the placebo group (hazard ratio, 0.76; 95% confidence interval [CI], 0.64 to 0.91; P=0.002). The results for the second coprimary outcome were consistent with the results for the first (occurring in 277 participants [4.4%] in the rosuvastatin group and in 363 participants [5.7%] in the placebo group; hazard ratio, 0.75; 95% CI, 0.64 to 0.88; P<0.001). The results were also consistent in subgroups defined according to cardiovascular risk at baseline, lipid level, C-reactive protein level, blood pressure, and race or ethnic group. In the rosuvastatin group, there was no excess of diabetes or cancers, but there was an excess of cataract surgery (in 3.8% of the participants, vs. 3.1% in the placebo group; P=0.02) and muscle symptoms (in 5.8% of the participants, vs. 4.7% in the placebo group; P=0.005). CONCLUSIONS: Treatment with rosuvastatin at a dose of 10 mg per day resulted in a significantly lower risk of cardiovascular events than placebo in an intermediate-risk, ethnically diverse population without cardiovascular disease. (Funded by the Canadian Institutes of Health Research and AstraZeneca; HOPE-3 ClinicalTrials.gov number, NCT00468923.).},
	keywords = {Aged; Female; Middle Aged; Male; Humans; Double-Blind Method; Risk Factors; Cholesterol, LDL/blood; Medication Adherence; Hypercholesterolemia/*drug therapy; Rosuvastatin Calcium/*administration & dosage/adverse effects; Hydroxymethylglutaryl-CoA Reductase Inhibitors/*administration & dosage/adverse; Cardiovascular Diseases/ethnology/mortality/*prevention & control},
	year = {2016},
	eissn = {1533-4406},
	pages = {2021-2031},
	orcid-numbers = {Keltai, Katalin/0000-0002-8294-9062; Mezősi, Emese/0000-0001-9367-3877; Zsáry, András/0000-0002-4994-1448}
}

@article{MTMT:1277662,
	title = {Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)},
	url = {https://m2.mtmt.hu/api/publication/1277662},
	doi = {10.1016/S0140-6736(03)14286-9},
	journal-iso = {LANCET},
	journal = {LANCET},
	volume = {362},
	unique-id = {1277662},
	issn = {0140-6736},
	abstract = {Background Treatment with angiotensin-converting-enzyme (ACE) inhibitors reduces the rate of cardiovascular events among patients with left-ventricular dysfunction and those at high risk of such events. We assessed whether the ACE inhibitor perindopril reduced cardiovascular risk in a low-risk population with stable coronary heart disease and no apparent heart failure. Methods We recruited patients from October, 1997, to June, 2000. 13 655 patients were registered with previous myocardial infarction (64%), angiographic evidence of coronary artery disease (61%), coronary revascularisation (55%), or a positive stress test only (5%). After a run-in period of 4 weeks, in which all patients received perindopril, 12 218 patients were randomly assigned perindopril 8 mg once daily (n=6110), or matching placebo (n=6108). The mean follow-up was 4.2 years, and the primary endpoint was cardiovascular death, myocardial infarction, or cardiac arrest. Analysis was by intention to treat. Findings Mean age of patients was 60 years (SD 9), 85% were male, 92% were taking platelet inhibitors, 62% beta blockers, and 58% lipid-lowering therapy. 603 (10%) placebo and 488 (8%) perindopril patients experienced the primary endpoint, which yields a 20% relative risk reduction (95% CI 9-29, p=0.0003) with perindopril. These benefits were consistent in all predefined subgroups and secondary endpoints. Perindopril was well tolerated. Interpretation Among patients with stable coronary heart disease without apparent heart failure, perindopril can significantly improve outcome. About 50 patients need to be treated for a period of 4 years to prevent one major cardiovascular event. Treatment with perindopril, on top of other preventive medications, should be considered in all patients with coronary heart disease.},
	year = {2003},
	eissn = {1474-547X},
	pages = {782-788},
	orcid-numbers = {Jánosi, András/0000-0003-3603-1004}
}